TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05865990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab deruxtecan
Description: HER3 directed antibody drug conjugate (ADC) that is comprised of a fully human anti-HER3 immunoglobulin gamma-1 (IgG1) monoclonal antibody attached to a topoisomerase I inhibitor payload (an exatecan derivative, DXd) via a stable tetrapeptide-based cleavable linker.
Study: NCT04897711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceptual Training
Description: Each listener is familiarized/trained with a single speaker with dysarthria. Pretest/posttest transcription data will be used to build explanatory models of intelligibility improvement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceptual Training
Description: Each listener is familiarized/trained with a single speaker with dysarthria. Pretest/posttest transcription data will be used to build explanatory models of intelligibility improvement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceptual Training
Description: Each listener is familiarized/trained with a single speaker with dysarthria. Pretest/posttest transcription data will be used to build explanatory models of intelligibility improvement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceptual Training
Description: Each listener is familiarized/trained with a single speaker with dysarthria. Pretest/posttest transcription data will be used to build explanatory models of intelligibility improvement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceptual Training
Description: Each listener is familiarized/trained with a single speaker with dysarthria. Pretest/posttest transcription data will be used to build explanatory models of intelligibility improvement.
Study: NCT06198933

Intervention type: DEVICE
Intervention: Pulsed-field ablation
Description: Patients will atrial fibrillation will undergo catheter ablation using pulsed-field energy
Study: NCT06285825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emapalumab
Description: Given by Infusion
Study: NCT05222529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium bromide 25ug
Description: 25μg Glycopyrronium bromide capsules for oral inhalation via Breezhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium bromide 25ug
Description: 25μg Glycopyrronium bromide capsules for oral inhalation via Breezhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glycopyrronium bromide 25ug
Description: 25μg Glycopyrronium bromide capsules for oral inhalation via Breezhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to Glycopyrronium bromide capsules for oral inhalation via Breezhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to Glycopyrronium bromide capsules for oral inhalation via Breezhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Glycopyrronium bromide capsules for oral inhalation via Breezhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium bromide 12.5ug
Description: 12.5ug Glycopyrronium bromide capsules for oral inhalation via Breezhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium bromide 12.5ug
Description: 12.5ug Glycopyrronium bromide capsules for oral inhalation via Breezhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glycopyrronium bromide 12.5ug
Description: 12.5ug Glycopyrronium bromide capsules for oral inhalation via Breezhaler
Study: NCT04408989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB02-SP
Description: Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB02-DM
Description: Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US licenced Avastin®
Description: Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
Study: NCT05015426

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gamma Delta T-Cell Infusion
Description: Donor cells will be processed in a laboratory, where T-cell subtype called γδ (gamma delta) T-cells will be isolated and expanded in number. These T-cells expanded in a laboratory will be infused in participants who are otherwise at high risk of AML recurrence after alloHCT.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gamma Delta T-Cell Infusion
Description: Donor cells will be processed in a laboratory, where T-cell subtype called γδ (gamma delta) T-cells will be isolated and expanded in number. These T-cells expanded in a laboratory will be infused in participants who are otherwise at high risk of AML recurrence after alloHCT.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gamma Delta T-Cell Infusion
Description: Donor cells will be processed in a laboratory, where T-cell subtype called γδ (gamma delta) T-cells will be isolated and expanded in number. These T-cells expanded in a laboratory will be infused in participants who are otherwise at high risk of AML recurrence after alloHCT.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gamma Delta T-Cell Infusion
Description: Donor cells will be processed in a laboratory, where T-cell subtype called γδ (gamma delta) T-cells will be isolated and expanded in number. These T-cells expanded in a laboratory will be infused in participants who are otherwise at high risk of AML recurrence after alloHCT.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gamma Delta T-Cell Infusion
Description: Donor cells will be processed in a laboratory, where T-cell subtype called γδ (gamma delta) T-cells will be isolated and expanded in number. These T-cells expanded in a laboratory will be infused in participants who are otherwise at high risk of AML recurrence after alloHCT.
Study: NCT06277687

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Virtual Augmented Reality Combined With Finder
Description: After CT examination, the computer carried out three-dimensional reconstruction of blood vessels, and input the CTA data into Cinematic Anatomy reconstruction software to analyze blood vessels, Muscles and other tissues are reconstructed in three dimensions. Before the operation, the Finder is used to restore the position of the thigh during CTA examination. The Hololens is used to match the reconstructed three-dimensional image with the perforator locator and the thigh. Before the operation, the pedicles of the descending branches of the lateral arteries and the perforating vessels are marked on the skin of the thigh to achieve the positioning and marking of the perforating branches.
Study: NCT04232566

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Evaluate liver fibrosis by elastography before gastric bypass surgery.
Study: NCT06261021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 1.5% cream
Description: Topical application of Ruxolitinib 1.5% cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 1.5% cream
Description: Topical application of Ruxolitinib 1.5% cream

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application without occlusion in Area 1
Description: Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion without occlusion on Area 1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application under occlusion at night in Area 2
Description: Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion under occlusion at night on Area 2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application under occlusion at night in Area 1
Description: Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion under occlusion at night on Area 1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application without occlusion in Area 2
Description: Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion without occlusion on Area 2.
Study: NCT05804747

Intervention type: DRUG
Intervention: Edoxaban
Description: This is observational, non-interventional study. No study drug will be administered during this study.
Study: NCT04672239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone app Smiling instead of Smoking (SiS) Version 3
Description: Participants will be onboarded to the smartphone app SiS and will be asked to use it for 7 weeks to support them in quitting smoking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone app QuitGuide (QG)
Description: Participants will be onboarded to the NCI smartphone app QG and will be asked to use it for 7 weeks to support them in quitting smoking.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brochure Clearing the Air (CTA)
Description: Participants will be onboarded to the brochure Clearing the Air and will be asked to use it for 7 weeks to support them in quitting smoking.
Study: NCT06196008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend telephone-based coaching sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive written educational materials on physical activity and standard preoperative care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Receive a personalized physical activity program, set fitness goals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear activity monitor

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Wear activity monitor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Performance Testing
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04074044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BHmApp
Description: Use of BHmApp for bladder education and training in pregnancy
Study: NCT05079334

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MeTree Questionnaire
Description: MeTree is a patient driven risk assessment program with Clinical Decision Support (CDS) that enables collection of a three plus generation family health history (FHH) on 128 conditions. CDS is provided in a report with a pedigree and tailored evidence-based guidelines. While patient drive, MeTree also includes a provider-facing report with additional references. These reports promote engagement by both patients and providers and enhance shared decision-making.~MeTree first generates information imported from the participant's EHR record. These data include basic demographic information, any recent lab results, and any listed diseases or conditions from the EHR. Next, MeTree gives the participant an opportunity to fill out a family history tree. The more information the participant provides on their own health and their family member's health, the better MeTree can provide recommendations from current literature.
Study: NCT05760365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printed educational model
Description: 3D printed cardiac catheterization model

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Slide-based presention
Description: Slide-based presention
Study: NCT05857995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program
Description: KLCLCSC is a survivor or survivor plus caregiver-focused psychosocial and behavioral intervention designed to engage lung cancer survivors and improve lung cancer outcomes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: EUC involves a combination of the standard of care plus a bibliotherapy intervention and assessment.
Study: NCT06132243

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Jaktinib Hydrochloride Tablets
Description: Orally, one tablet at a time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablets
Description: Orally, one tablet at a time
Study: NCT06372678

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM326
Description: CM326 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM326
Description: CM326 injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04866446

Intervention type: DEVICE
Intervention: endotracheal intubation and laringeal mask airway insertion
Description: endotracheal intubation and laringeal mask airway insertion on the airway manikin with different devices

Intervention type: DEVICE
Intervention: endotracheal intubation and laringeal mask airway insertion
Description: endotracheal intubation and laringeal mask airway insertion on the airway manikin with different devices
Study: NCT06407414

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: classical physiotherapy methods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: In addition to classical physiotherapy methods, neuromuscular exercise protocol will be applied.
Study: NCT06002919

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MindWalk Intervention
Description: The intervention will include: 1) a mindful walking training followed by 2) a prescribed mindful walking regimen, 3) self-reporting of adherence to regimen by the participants using activity logbooks and use of a user-friendly PA tracker (Fitbit) for daily step count, and 4) personalized text messages with reminders and motivational messages for participants to do the mindful walking as prescribed including a weekly check-in call or text message for accountability.
Study: NCT06052319

Intervention type: DEVICE
Intervention: Care4Today® Connect CAD-PAD Mobile Application
Description: Participants will not receive any drug intervention in this study. Participants will use Care 4Today® Connect CAD-PAD mobile application for 3 months. The study will assess participant engagement and usefulness.
Study: NCT05194124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide 2 mg
Description: Administered as SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide 2.5 mg
Description: Administered as SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide 3 mg
Description: Administered as SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide 3 mg
Description: Administered as SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide 20 mg
Description: Administered as SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide 20 mg
Description: Administered as SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide 25 mg
Description: Administered as SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide 25 mg
Description: Administered as SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide 30 mg
Description: Administered as SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide 30 mg
Description: Administered as SC injection
Study: NCT05524493

Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI
Description: We will examine migraine and epilepsy patients as well as healthy controls using resting-state and task fMRI (including sensory stimulation using pain stimulus) in both brain and spinal cord.

Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI
Description: We will examine migraine and epilepsy patients as well as healthy controls using resting-state and task fMRI (including sensory stimulation using pain stimulus) in both brain and spinal cord.

Intervention type: DIAGNOSTIC_TEST
Intervention: MR Spectroscopy
Description: We will examine migraine and epilepsy patients as well as healthy controls using MR Spectroscopy in both brain and spinal cord.

Intervention type: DIAGNOSTIC_TEST
Intervention: MR Spectroscopy
Description: We will examine migraine and epilepsy patients as well as healthy controls using MR Spectroscopy in both brain and spinal cord.

Intervention type: DIAGNOSTIC_TEST
Intervention: MR Spectroscopy
Description: We will examine migraine and epilepsy patients as well as healthy controls using MR Spectroscopy in both brain and spinal cord.

Intervention type: DIAGNOSTIC_TEST
Intervention: MR Spectroscopy
Description: We will examine migraine and epilepsy patients as well as healthy controls using MR Spectroscopy in both brain and spinal cord.
Study: NCT05270174

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT05023681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Staphylokinase
Description: Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Intravenous injection of placebo(normal saline ) is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
Study: NCT05031663

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almond group
Description: Participants in the Almond group will receive 15% of their daily energy intake in the form of almonds as a snack

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Participants in the control group will receive an isocaloric carbohydrate based commercial snack (pretzel)
Study: NCT04727268

Intervention type: OTHER
Intervention: No intervention
Description: No interventions present in this study.
Study: NCT05769569

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: VRC07-523LS is a recombinant human immunoglobulin G1 (IgG1) broadly neutralizing monoclonal antibody (bNAb) directed against the HIV-1 CD4 binding site. Intravenous infusion of 10 mg/kg VRC07-523LS will be administered on Week 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400LS
Description: PGDM1400LS is a recombinant human IgG1 bNAb targeted against the HIV-1 V2 apex epitope region. Intravenous infusion of 20 mg/kg PGDM1400LS will be administered on Week 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: N-803 is a recombinant human superagonist interleukin-15 (IL-15) complex. N-803 at 6 ug/kg will be administered via subcutaneous injection to the trunk on Weeks 1, 4, 7, 39, 42 and 45.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos4.HIV
Description: Ad26.Mos4.HIV is a tetravalent vaccine comprising Ad26.Mos1.Env, Ad26.Mos2S.Env, Ad26.Mos1.Gag-Pol, and Ad26.Mos2.Gag-Pol. Ad26.Mos4.HIV at 5x1010 viral particles (per 0.5 mL dose) will be administered through intramuscular injection in the quadriceps muscle at Week 11.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-HIV
Description: MVA-BN-HIV is a single vector recombinant Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN®) expressing Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol. MVA-BN-HIV at 2x108 infectious unit (per 0.5mL dose) will be administered through intramuscular injection in the quadriceps muscle at Week 35.
Study: NCT05914766

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PATHWAYS
Description: The PATHWAYS intervention is a psychoeducational intervention comprised of three components.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PATHWAYS
Description: The PATHWAYS intervention is a psychoeducational intervention comprised of three components.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: The enhanced usual care condition consists of an information resource guide.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: The enhanced usual care condition consists of an information resource guide.
Study: NCT05769569

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A244d11 gp120
Description: A244d11 gp120, consists of the gp120 envelope glycoprotein HIV-1 subtype CRF_01AE A244 derived from the CM244 CRF_01AE strain, with an 11 amino N-terminal deletion. It is a modification of the A244 rgp120 immunogen from the AIDSVAX®B/E vaccine. A244d11 gp120 at 300 ug will be administered as an intramuscular injection in the quadriceps muscle at week 11 and week 35.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALFQ
Description: ALFQ (Army Liposome Formulation, ALF) is a liposomal adjuvant containing a synthetic monophosphoryl lipid A (MPLA, 3D-PHAD®) with the addition of QS-21. ALFQ at 200 ug will be administered as an intramuscular injection in the quadriceps muscle at week 11 and week 35.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy (ART)
Description: This study will enroll PLWH aged 18-50 years who initiated ART during Fiebig I-V AHI and are virologically suppressed (HIV RNA \<50 copies/ml for ≥48 weeks) on uninterrupted ART, who meet study inclusion criteria in Bangkok, Thailand.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral Therapy (ART)
Description: This study will enroll PLWH aged 18-50 years who initiated ART during Fiebig I-V AHI and are virologically suppressed (HIV RNA \<50 copies/ml for ≥48 weeks) on uninterrupted ART, who meet study inclusion criteria in Bangkok, Thailand.
Study: NCT06127823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary treatment
Description: Dietary counselling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary treatment
Description: Dietary counselling
Study: NCT05011773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Electrical pulses from implanted generator that has already been implanted for therapeutic reasons